



September 2009

2007 trial published in Gynecologic Oncology

Zilico's 2007 study on the use of its device as an adjunct to colposcopy in the diagnosis of high grade CIN has been published in the American journal Gynecologic Oncology. The data confirms that the device has the potential to be used as an adjunct to colposcopy in the diagnosis of high grade CIN. It has the advantage of real time results, decreasing the need for diagnostic cervical biopsies, and facilitates a wider use of the 'see and treat' policy without the risk of over-treatment.

This trial brings the clinical data set to over 500 women in total and further underwrites the potential of the device in helping to manage cervical cancer. The device is now in a EU multi-centre trial.

This article, *Balasubramani L, et al, The detection of cervical intraepithelial neoplasia by electrical impedance spectroscopy: The effects of acetic acid and tissue homogeneity, Gynecol Oncol (2009)* is available on-line at, <http://dx.doi.org/10.1016/j.ygyno.2009.08.010>.

For more information please contact: Sameer Kothari, CEO, Zilico Ltd, tel: 0114 222 4580; email: sameer.kothari@zilico.co.uk

Notes for editors:

Zilico Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two product applications are under development: the first for the referral market and the second for the screening market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures.

Zilico has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal, pre-cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Zilico's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Zilico (previously known as Aperio Diagnostic Ltd) has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Zilico product applications consist of a handheld device and a base unit together with a single-use disposable sleeve for each test.